title: Circulatory changes of the novel adipokine adipolin/CTRP12 in response to metformin treatment and an oral glucose challenge in humans.
abstract: OBJECTIVE
  Adipolin/CTRP12 is a novel adipokine with anti-inflammatory and glucose-lowering properties in rodents. We sought to investigate the effects of metformin treatment (850 mg twice daily for 6 months) and a 2 h 75 g oral glucose tolerance test (OGTT) on serum adipolin concentrations in humans.
  
  
  METHODS
  Cross-sectional study [PCOS (n = 83) and control (n = 39) subjects]. Serum adipolin was measured by ELISA. Metformin treatment (850 mg twice daily for 6 months) was offered to all women with PCOS, 34 women participated but 21 women completed 6 months of metformin therapy. Reasons for subjects not completing the study were nausea and gastrointestinal side effects (n = 4), pregnancies (n = 5), noncompliance (n = 2) and loss of contact (n = 2).
  
  
  RESULTS
  Metformin treatment (850 mg twice daily for 6 months) substantially increased serum adipolin concentrations (P < 0·05) in women with polycystic ovary syndrome (PCOS), a pro-inflammatory state associated with obesity, diabetes, dyslipidaemia and atherosclerosis. Furthermore, changes in waist-hip ratio, glucose, triglycerides, CRP and carotid intima media thickness showed significant negative associations with changes in adipolin levels (P < 0·05, P < 0·01); in multiple regression analyses, only changes in glucose were predictive of changes in adipolin levels (β = -0·570, P = 0·009). Serum adipolin decreased significantly in response to the OGTT in PCOS and control subjects at 90 min (P < 0·05) and 120 min (P < 0·01).
  
  
  CONCLUSIONS
  Adipolin and/or novel pharmacologic agents that increase adipolin's circulating concentrations might constitute a novel approach in the treatment of insulin resistant states.
authors.affiliation: Warwick Medical School, University of Warwick, Coventry, UK; Department of Obstetrics and Gynaecology, Birmingham Heartlands and Solihull Hospitals, Heart of England NHS Foundation Trust, Birmingham, UK.
authors.forename: Bee K
authors.initials: BK
authors.lastname: Tan
authors.forename: Jing
authors.initials: J
authors.lastname: Chen
authors.forename: Jiamiao
authors.initials: J
authors.lastname: Hu
authors.forename: Omar
authors.initials: O
authors.lastname: Amar
authors.forename: Harman S
authors.initials: HS
authors.lastname: Mattu
authors.forename: Manjunath
authors.initials: M
authors.lastname: Ramanjaneya
authors.forename: Vanlata
authors.initials: V
authors.lastname: Patel
authors.forename: Hendrik
authors.initials: H
authors.lastname: Lehnert
authors.forename: Harpal S
authors.initials: HS
authors.lastname: Randeva
mesh_terms: D054392:Adipokines / Q000097:blood*; D000328:Adult; D001786:Blood Glucose / Q000378:metabolism*; D059168:Carotid Intima-Media Thickness; D016022:Case-Control Studies; D003430:Cross-Sectional Studies; D005260:Female; D005951:Glucose Tolerance Test; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D007333:Insulin Resistance; D008687:Metformin / Q000627:therapeutic use*; D009765:Obesity / Q000378:metabolism; D011085:Polycystic Ovary Syndrome / Q000188:drug therapy* / Q000378:metabolism; D016896:Treatment Outcome; D049629:Waist-Hip Ratio; D055815:Young Adult
chemical_list: D054392:Adipokines; D001786:Blood Glucose; C584654:C1QTNF12 protein, human; D007004:Hypoglycemic Agents; D008687:Metformin